Brokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) PT at $43.33

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) has earned a consensus rating of "Buy" from the six brokerages that are presently covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have covered the stock in the last year is $43.33.

NAMS has been the topic of a number of research reports. Scotiabank boosted their target price on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Thursday, February 27th. UBS Group set a $41.00 target price on NewAmsterdam Pharma in a report on Monday, March 3rd. HC Wainwright reissued a "buy" rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $40.00 price objective on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $42.00 target price on shares of NewAmsterdam Pharma in a research report on Tuesday, April 8th.

NewAmsterdam Pharma Stock Performance

Shares of NewAmsterdam Pharma stock remained flat at $20.03 during trading on Wednesday. The stock had a trading volume of 487,846 shares, compared to its average volume of 602,784. NewAmsterdam Pharma has a 12 month low of $14.06 and a 12 month high of $27.29. The stock has a market cap of $2.20 billion, a P/E ratio of -7.70 and a beta of -0.01. The company has a fifty day simple moving average of $19.68 and a 200-day simple moving average of $21.24.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.95) EPS for the quarter, missing analysts' consensus estimates of ($0.48) by ($0.47). The firm had revenue of $12.77 million for the quarter, compared to analysts' expectations of $3.30 million. As a group, sell-side analysts anticipate that NewAmsterdam Pharma will post -1.75 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director James N. Topper bought 1,135 shares of the stock in a transaction that occurred on Wednesday, March 26th. The stock was acquired at an average price of $22.49 per share, with a total value of $25,526.15. Following the completion of the purchase, the director now directly owns 3,013,569 shares of the company's stock, valued at approximately $67,775,166.81. This represents a 0.04 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, CAO Louise Frederika Kooij sold 150,000 shares of the stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the sale, the chief accounting officer now owns 15,000 shares of the company's stock, valued at approximately $305,550. The trade was a 90.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 19.50% of the company's stock.

Institutional Trading of NewAmsterdam Pharma

Several large investors have recently modified their holdings of NAMS. Arizona State Retirement System acquired a new position in shares of NewAmsterdam Pharma during the 1st quarter valued at $215,000. Alps Advisors Inc. boosted its position in shares of NewAmsterdam Pharma by 4.4% during the 1st quarter. Alps Advisors Inc. now owns 77,961 shares of the company's stock worth $1,596,000 after purchasing an additional 3,252 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of NewAmsterdam Pharma by 12.5% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 22,028 shares of the company's stock valued at $451,000 after buying an additional 2,439 shares during the period. Lisanti Capital Growth LLC increased its position in NewAmsterdam Pharma by 26.9% in the 1st quarter. Lisanti Capital Growth LLC now owns 49,110 shares of the company's stock valued at $1,005,000 after buying an additional 10,395 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in NewAmsterdam Pharma by 19.4% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock worth $80,000 after buying an additional 596 shares during the period. Institutional investors and hedge funds own 89.89% of the company's stock.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.